Breaking News Instant updates and real-time market news.

PGNX

Progenics

$5.86

-0.03 (-0.51%)

08:46
07/08/19
07/08
08:46
07/08/19
08:46

Progenics urges shareholders to vote for its director candidates

Progenics Pharmaceuticals encourages all shareholders to vote "FOR" all of the Board's highly qualified and engaged nominees online or by telephone by following the easy instructions on the "WHITE" Proxy Card. The company said, "The Board unanimously recommends the election of Peter Crowley, Mark Baker and Michael Kishbauch, all of whom have played an instrumental role in the creation and development of the Company's strategy that has resulted in key advancements in our oncology pipeline, and continue to be critical to Progenics' long-term success. Here are the facts: Progenics is achieving significant progress in advancing life-saving treatments for cancer. Progenics is making progress on its strategy and is working diligently to advance its pipeline and make a difference in the lives of patients. The Board and management team have been integral to the successful development and execution of the Company's strategic business plan, which has now delivered the first commercial sale of AZEDRA. Progenics' Board has the right expertise and is best-positioned to hold management accountable and guide the Company to long-term success. The Board is and has been central to the successful implementation of Progenics' strategy, and is committed to enhancing value for all shareholders. The removal of any of the Board's directors would risk derailing the Company at a key inflection point...Velan Capital is attempting to derail our significant progress and ultimately to gain control of the Board at the expense of ALL Progenics shareholders. The addition of any of Velan's candidates - all of whom are interconnected through a web of past experiences and some of whom are associated with unlawful pricing practices - will introduce substantial risk to shareholders and key constituencies. Velan has demonstrated its lack of understanding of and commitment to Progenics' business on multiple occasions, and its candidates lack the requisite experience to contribute effectively to the Board. The Company is at a crucial moment of growth that calls for an experienced Board with a clear commitment to ESG principles...The Board continues to be open to reaching a constructive settlement with Velan...Leading independent proxy advisory firms Glass Lewis and Egan-Jones endorse Progenics' directors and recommend that shareholders vote on Progenics' WHITE card for ALL of the Company's directors."

PGNX Progenics
$5.86

-0.03 (-0.51%)

07/31/18
NEED
07/31/18
NO CHANGE
Target $16
NEED
Strong Buy
Progenics price target raised to $16 from $14 at Needham
Needham analyst Chad Messer raised his price target on Progenics to $16 after the FDA approved Azedra for intravenous use for certain types of locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. Messer keeps a Strong Buy rating on Progenics shares.
09/13/18
NEED
09/13/18
DOWNGRADE
NEED
Buy
Progenics downgraded to Buy from Strong Buy at Needham
09/13/18
09/13/18
DOWNGRADE
Target $12

Buy
Progenics downgraded to Buy on Phase III trial disappointment at Needham
As previously reported, Needham analyst Chad Messer downgraded Progenics to Buy from Strong Buy after its Phase III study of PSMA imaging agent 1404 in prostate cancer missed its co-primary sensitivity endpoint. Although the study did meet the specificity endpoint, the analyst believes these results fall short of expectations set based on strong Phase II results. Additionally, Messer notes that the limitations of 1404 are likely due to the SPECT/CT platform and sees no read through to PyL, Progenic's other PSMA based imaging agent that works on the more sensitive PET imaging platform. The analyst also lowered his price target on the shares to $12 from $16.
12/07/18
FBCO
12/07/18
INITIATION
Target $6.5
FBCO
Outperform
Progenics initiated with an Outperform at Credit Suisse
Credit Suisse analyst Martin Auster initiated Progenics with an Outperform rating and $6.50 price target. In a research note to investors, Auster says he believes Progenics' royalties and future milestones from Relistor and revenue from Azedra support a core business with an NPV of about $5 per share, and says that as the commercial uptake of Azedra begins to unfold, investor focus is expected to turn to upside opportunities in prostate cancer PSMA-targeting diagnostic and therapeutic approaches. He adds that Novartis' (NVS) recent $2.1B acquisition of Endocyte (ECYT) supports pharma interest and attractive valuations in the space.

TODAY'S FREE FLY STORIES

AAPL

Apple

$204.77

1.45 (0.71%)

, SWKS

Skyworks

$81.00

0.85 (1.06%)

14:12
07/18/19
07/18
14:12
07/18/19
14:12
On The Fly
Street Fight: Apple upgraded on 5G iPhone hopes as analysts diverge on Skyworks »

Citing greater confidence…

AAPL

Apple

$204.77

1.45 (0.71%)

SWKS

Skyworks

$81.00

0.85 (1.06%)

QCOM

Qualcomm

$74.67

-1.08 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 31

    Jul

  • 07

    Aug

QCOM

Qualcomm

$74.67

-1.08 (-1.43%)

14:09
07/18/19
07/18
14:09
07/18/19
14:09
Initiation
Qualcomm initiated  »

Qualcomm initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

MSFT

Microsoft

$135.02

-1.21 (-0.89%)

, AMZN

Amazon.com

$1,958.83

-33.58 (-1.69%)

14:05
07/18/19
07/18
14:05
07/18/19
14:05
Periodicals
Trump says he's considering looking into Pentagon's JEDI contract, CNBC says »

U.S. President Donald…

MSFT

Microsoft

$135.02

-1.21 (-0.89%)

AMZN

Amazon.com

$1,958.83

-33.58 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 25

    Jul

  • 06

    Aug

  • 08

    Aug

EGBN

Eagle Bancorp

$44.62

-8.81 (-16.49%)

14:02
07/18/19
07/18
14:02
07/18/19
14:02
Downgrade
Eagle Bancorp rating change  »

Eagle Bancorp downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 15

    Aug

  • 11

    Sep

  • 23

    Sep

14:00
07/18/19
07/18
14:00
07/18/19
14:00
General news
Breaking General news story  »

New York Federal Reserve…

13:55
07/18/19
07/18
13:55
07/18/19
13:55
Conference/Events
Federal Reserve Bank of New York president delivers keynote address »

New York Federal Reserve…

CAMP

CalAmp

$10.59

-0.23 (-2.13%)

13:55
07/18/19
07/18
13:55
07/18/19
13:55
Conference/Events
CalAmp participates in a conference call with Northland »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Jul

  • 06

    Aug

ADMP

Adamis Pharmaceuticals

$1.22

-0.03 (-2.41%)

13:54
07/18/19
07/18
13:54
07/18/19
13:54
Hot Stocks
Adamis Pharmaceuticals, kaleo Inc agree to settle all litigation »

Adamis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

PPG

PPG

$116.58

-0.025 (-0.02%)

13:54
07/18/19
07/18
13:54
07/18/19
13:54
Earnings
PPG sees unfavorable currency translation impact on Q3 sales of $30M-$50M »

"Looking ahead,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Aug

PPG

PPG

$116.49

-0.115 (-0.10%)

13:49
07/18/19
07/18
13:49
07/18/19
13:49
Hot Stocks
PPG says Q2 EPS impacted by lower global industrial production »

According to prepared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Aug

ZBRA

Zebra Technologies

$180.92

-16.74 (-8.47%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Options
Notable vol spike in Zebra Technologies as shares sell off »

Notable vol spike in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$6.98

0.31 (4.65%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Recommendations
Tellurian analyst commentary at Stifel »

Tellurian higher after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JLL

Jones Lang LaSalle

$140.05

0.585 (0.42%)

13:32
07/18/19
07/18
13:32
07/18/19
13:32
Conference/Events
Jones Lang LaSalle management to meet with Mizuho »

Meeting with EVP Monahan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

  • 06

    Aug

GOSS

Gossamer Bio

$19.60

-0.48 (-2.39%)

13:30
07/18/19
07/18
13:30
07/18/19
13:30
Options
Gossamer Bio call volume spikes on November purchase wit shares at 52wk lows »

Gossamer Bio call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
07/18/19
07/18
13:25
07/18/19
13:25
Conference/Events
Cowen healthcare/biotech analysts to hold an analyst/industry conference call »

Healthcare Technology…

PEP

PepsiCo

$132.17

-0.6 (-0.45%)

13:24
07/18/19
07/18
13:24
07/18/19
13:24
Periodicals
Breaking Periodicals news story on PepsiCo »

PepsiCo in talks to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
07/18/19
07/18
13:20
07/18/19
13:20
General news
Treasury's $14 B 10-year TIPS sale was on the soft side »

Treasury's $14 B…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/18/19
07/18
13:17
07/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/18/19
07/18
13:16
07/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$8.55

-0.03 (-0.35%)

13:15
07/18/19
07/18
13:15
07/18/19
13:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

TELL

Tellurian

$6.99

0.32 (4.80%)

13:05
07/18/19
07/18
13:05
07/18/19
13:05
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:57
07/18/19
07/18
12:57
07/18/19
12:57
Conference/Events
Stephens architecture analysts to hold analyst/industry conference call nosymbol »

Analysts hold an…

EMR

Emerson

$64.26

-0.4 (-0.62%)

12:55
07/18/19
07/18
12:55
07/18/19
12:55
Options
Emerson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

  • 22

    Aug

  • 06

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.